Quest Group acquired a portfolio of technology and IP from Vitae Pharmaceuticals and announced it completed a $20 million private placement. Quest says the portfolio involves "nuclear receptors with new-generation oncology product candidates for blood and solid tumor cancers and cancer supportive care."
"Quest now represents the single largest concentration of retinoid/rexinoid therapeutics in the world," says Dr. Parkash Gill, chairman of Quest's scientific advisory board. "The company hopes to deliver on the promise of these therapeutics to drive tumor cells towards differentiation and/cell death. This approach may also incorporate rational combination with other therapeutics."
- check out the release for more information